ATE212627T1 - Farnesyltransferase hemmende 2-chinolonderivate - Google Patents

Farnesyltransferase hemmende 2-chinolonderivate

Info

Publication number
ATE212627T1
ATE212627T1 AT96937249T AT96937249T ATE212627T1 AT E212627 T1 ATE212627 T1 AT E212627T1 AT 96937249 T AT96937249 T AT 96937249T AT 96937249 T AT96937249 T AT 96937249T AT E212627 T1 ATE212627 T1 AT E212627T1
Authority
AT
Austria
Prior art keywords
quinolone derivatives
farnesyltransferase inhibiting
farnesyltransferase
inhibiting
quinolone
Prior art date
Application number
AT96937249T
Other languages
English (en)
Inventor
David William End
Marc Gaston Venet
Patrick Rene Angibaud
Gerard Charles Sanz
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE212627T1 publication Critical patent/ATE212627T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT96937249T 1995-10-31 1996-10-25 Farnesyltransferase hemmende 2-chinolonderivate ATE212627T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95202945 1995-10-31
PCT/EP1996/004661 WO1997016443A1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives

Publications (1)

Publication Number Publication Date
ATE212627T1 true ATE212627T1 (de) 2002-02-15

Family

ID=8220785

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01200450T ATE269322T1 (de) 1995-10-31 1996-10-25 Farnesyltransferase hemmende 2-chinolonderivate
AT96937249T ATE212627T1 (de) 1995-10-31 1996-10-25 Farnesyltransferase hemmende 2-chinolonderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01200450T ATE269322T1 (de) 1995-10-31 1996-10-25 Farnesyltransferase hemmende 2-chinolonderivate

Country Status (28)

Country Link
US (1) US5968952A (de)
EP (2) EP1019395B1 (de)
JP (1) JP4257869B2 (de)
KR (1) KR100417620B1 (de)
CN (1) CN1101391C (de)
AR (1) AR004699A1 (de)
AT (2) ATE269322T1 (de)
AU (1) AU712435B2 (de)
CA (1) CA2231143C (de)
CY (1) CY2287B1 (de)
CZ (1) CZ290954B6 (de)
DE (2) DE69632751T2 (de)
DK (1) DK1019395T3 (de)
EA (1) EA000719B1 (de)
ES (2) ES2171736T3 (de)
HU (1) HU224032B1 (de)
IL (1) IL123567A (de)
MY (1) MY116577A (de)
NO (1) NO314037B1 (de)
NZ (1) NZ321576A (de)
PL (1) PL184168B1 (de)
PT (1) PT1019395E (de)
SI (1) SI1019395T1 (de)
SK (1) SK282642B6 (de)
TR (1) TR199800720T2 (de)
TW (1) TW349948B (de)
WO (1) WO1997016443A1 (de)
ZA (1) ZA969087B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740603B2 (en) * 1997-06-02 2001-11-08 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
DK1037880T3 (da) 1997-12-11 2004-11-15 Janssen Pharmaceutica Nv Anilider som retinsyremimetika
DK1097150T3 (da) * 1998-06-16 2004-07-26 Sod Conseils Rech Applic Imidazolylderivater
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ID26987A (id) 1998-07-06 2001-02-22 Janssen Pharmaceutica Nv Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
ID27562A (id) 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
ES2237125T3 (es) 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
WO2000034239A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000034437A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ID29241A (id) * 1998-12-23 2001-08-16 Janssen Pharmaceutica Nv Turunan-turunan kinolin teranelasi-1,2
PL349839A1 (en) 1999-02-11 2002-09-23 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (de) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazol-Derivate
PT1106612E (pt) 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6838467B2 (en) 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
JP2003525252A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
CA2397448A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US20030078281A1 (en) * 2000-02-29 2003-04-24 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
US20030027808A1 (en) * 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064196A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
EP1261343A2 (de) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Kombination von farnesyl proteintransferase inhibitoren mit antitumor wirksamen nukleosid-derivaten
AU2001244167A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
AU2001252147A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations
WO2001064194A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
EP1267871A2 (de) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Kombination von farnesyl proteintransferase inhibitoren mit antitumor wirksamen podophyllotoxin-derivaten
JP2003525239A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
US7067531B2 (en) * 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
US7173040B2 (en) * 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
WO2002024682A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
JP4348080B2 (ja) * 2000-11-21 2009-10-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害するベンゾ複素環誘導体
DK1339407T3 (da) * 2000-11-28 2006-08-14 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
ES2260316T3 (es) * 2000-12-27 2006-11-01 Janssen Pharmaceutica N.V. Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
JP4351444B2 (ja) * 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−ヘテロシクリル−キノリンおよびキナゾリン誘導体
JP4969016B2 (ja) * 2001-02-15 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
BRPI0208075B8 (pt) 2001-03-12 2021-05-25 Janssen Pharmaceutica Nv processo para a preparação de compostos de imidazol
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
ATE425978T1 (de) 2001-12-19 2009-04-15 Janssen Pharmaceutica Nv Durch c-verbundene imidazole substituierte 1,8- annellierten chinolon-derivate als farnesyl transferase inhibitoren
JP4450628B2 (ja) * 2002-03-22 2010-04-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼインヒビターとして使用するためのベンジルイミダゾリル置換２−キノリンおよびキナゾリン誘導体
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
CA2580767A1 (en) * 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
HRP20130399T1 (hr) 2004-11-05 2013-06-30 Janssen Pharmaceutica Nv Terapeutska upotreba inhibitora farenziltransferaze i postupci praä†enja njihove efikasnosti
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
PL2021335T3 (pl) 2006-04-20 2011-10-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory kinazy C-FMS
WO2007124319A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
DE102007015709B4 (de) 2007-01-25 2009-09-03 Webasto Ag Fahrzeugdach
MY148609A (en) 2007-06-05 2013-05-15 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2009117484A2 (en) * 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
NZ593090A (en) 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物
WO2011127192A2 (en) 2010-04-06 2011-10-13 Brigham Young University Antimetastatic compounds
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
ES2705719T3 (es) 2010-07-28 2019-03-26 Janssen Diagnostics Llc Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa
US20130158035A1 (en) * 2010-08-24 2013-06-20 Brigham Young University Antimetastatic compounds
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103906751A (zh) * 2011-10-02 2014-07-02 波士顿大学董事会 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
ES2658773T3 (es) 2012-08-07 2018-03-12 Janssen Pharmaceutica N.V. Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo
US10653672B2 (en) 2014-02-07 2020-05-19 National University Corporation Tokyo Medical And Dental University Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
SMT202100712T1 (it) 2015-08-17 2022-01-10 Kura Oncology Inc Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi
EP3133065A1 (de) 2015-08-21 2017-02-22 Merck Patent GmbH Verbindungen für optisch aktive vorrichtungen
EP3133066A1 (de) * 2015-08-21 2017-02-22 Merck Patent GmbH Hydrophile verbindungen zur herstellung von optisch aktiven vorrichtungen
US9815790B2 (en) 2015-08-27 2017-11-14 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
TW201818965A (zh) 2016-11-03 2018-06-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法
EP3363786A1 (de) 2017-02-15 2018-08-22 Merck Patent GmbH Verbindungen für optisch aktive vorrichtungen
EP3363793A1 (de) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobe verbindungen zur herstellung von optisch aktiven vorrichtungen
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900501A (en) * 1970-12-23 1975-08-19 Hoffmann La Roche Benzophenone intermediates for 7-lower alkanoyl benzodiazepines
IL65709A (en) * 1981-05-18 1986-01-31 Chevron Res Electroactive polymers
JPS63275548A (ja) * 1987-05-02 1988-11-14 Res Inst For Prod Dev ｏ−アミノベンゾイル化合物の製造方法
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
EP0574992A1 (de) * 1992-06-17 1993-12-22 Glaxo Group Limited 5-(1,2,4-Triazol-1-Ylmethyl)-3H-Isobenzofuran-1-Onderivate, ihre Herstellung und Verwendung als Aromatasinhibitoren
ES2134971T3 (es) * 1994-04-15 1999-10-16 Takeda Chemical Industries Ltd Derivado de acido octahidro-2-naftaleno-carboxilico, su produccion y uso.

Also Published As

Publication number Publication date
JP4257869B2 (ja) 2009-04-22
MX9802067A (es) 1998-08-30
ES2171736T3 (es) 2002-09-16
AU712435B2 (en) 1999-11-04
DE69618999T2 (de) 2002-09-26
IL123567A (en) 2002-11-10
DE69632751D1 (de) 2004-07-22
EA000719B1 (ru) 2000-02-28
EP1019395B1 (de) 2002-01-30
AR004699A1 (es) 1999-03-10
JPH11514635A (ja) 1999-12-14
SK55698A3 (en) 1999-02-11
WO1997016443A1 (en) 1997-05-09
NZ321576A (en) 1999-05-28
CZ127298A3 (cs) 1998-12-16
NO980928D0 (no) 1998-03-04
DK1019395T3 (da) 2002-05-06
CA2231143C (en) 2005-06-21
HUP9802424A3 (en) 2003-02-28
CY2287B1 (en) 2003-07-04
PL184168B1 (pl) 2002-09-30
DE69618999D1 (de) 2002-03-14
HK1027576A1 (en) 2001-01-19
AU7493396A (en) 1997-05-22
EP1106610B1 (de) 2004-06-16
HK1036064A1 (en) 2001-12-21
TW349948B (en) 1999-01-11
US5968952A (en) 1999-10-19
CA2231143A1 (en) 1997-05-09
HU224032B1 (hu) 2005-05-30
EP1106610A1 (de) 2001-06-13
KR100417620B1 (ko) 2004-05-27
CN1101391C (zh) 2003-02-12
HUP9802424A2 (hu) 1999-10-28
ZA969087B (en) 1998-04-29
TR199800720T2 (xx) 1998-09-21
IL123567A0 (en) 1998-10-30
ES2233557T3 (es) 2005-06-16
NO980928L (no) 1998-04-29
SI1019395T1 (en) 2002-06-30
EA199800395A1 (ru) 1998-10-29
ATE269322T1 (de) 2004-07-15
DE69632751T2 (de) 2005-08-04
SK282642B6 (sk) 2002-10-08
PL328230A1 (en) 1999-01-18
CZ290954B6 (cs) 2002-11-13
KR19990063639A (ko) 1999-07-26
MY116577A (en) 2004-02-28
EP1019395A1 (de) 2000-07-19
PT1019395E (pt) 2002-07-31
NO314037B1 (no) 2003-01-20
CN1200732A (zh) 1998-12-02

Similar Documents

Publication Publication Date Title
ATE212627T1 (de) Farnesyltransferase hemmende 2-chinolonderivate
ATE289994T1 (de) Chinolin-derivate
DE69522717D1 (de) Chinazolinderivate
DE69611361D1 (de) Chinazolin-derivate
NO974103L (no) Arylsulfonylaminohydroksamsyre-derivater
DE69610698D1 (de) Chinazolin-derivate
ATE199150T1 (de) Diphenylmethylenpiperidin-derivate
NO964667D0 (no) Purin-6-on-derivater
DE69601527D1 (de) Pyrrolylbenzimidazol-Derivate
ATA100695A (de) Prothrombin-derivate
ATE240307T1 (de) Diarylalkenylamin-derivate
DE69627830D1 (de) Pyrazol-derivate
DE59607054D1 (de) 4-Amino-benzoylguanidin-Derivate
ATE177102T1 (de) Chromanderivate
DE59610106D1 (de) Fluorbenzylether-Derivate
DE69624122D1 (de) Aza-anthracyclinone-derivate
BR9603508A (pt) Derivados de alquenil-benzoilguanidina
DE59607055D1 (de) 4-Mercapto-benzoylguanidin-Derivate
DE69620514D1 (de) 5-aminoflavon-derivate
ATA45796A (de) Lysin-prolin-derivate
KR970025062U (ko) 근접센서 보호구
FI1822U1 (fi) Stoed-/skyddsorgan
BR9505290A (pt) Protect
DK0705833T3 (da) DC-89-derivat
BR9603733A (pt) Derivados de cloropiridilcarbonila

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee